Historical progress in the initial management of ovarian cancer: Intraperitoneal chemotherapy

摘要: Despite measured improvement in survival with the introduction of platinates and taxanes treatment advanced ovarian cancer, little additional progress has been made conventional cytotoxic agents. Recently, Gynecologic Oncology Group (GOG) published data from a study evaluating merits intraperitoneal chemotherapy women advanced, optimally cytoreduced cancer. They documented significant advantage progression-free overall for experimental regimen, combination intravenous paclitaxel cisplatin paclitaxel, compared standard chemotherapy. The regimen was substantially more toxic associated reduced short-term quality life. GOG trial joins six other phase III trials since 1994 comparing advanced-stage epithelial A recent meta-analysis suggests 21% reduction hazard progression (four studies) death (seven studies). Reluctance to adopt new care is rooted toxicity concerns. Further evaluation warranted clarify unanswered questions regarding administration schedule, agents, techniques, number courses, patient eligibility